Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Gross Margin (2016 - 2026)

Myriad Genetics has reported Gross Margin over the past 17 years, most recently at 69.97% for Q4 2025.

  • Quarterly Gross Margin fell 168.0% to 69.97% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 69.93% through Dec 2025, up 4.0% year-over-year, with the annual reading at 69.93% for FY2025, 4.0% up from the prior year.
  • Gross Margin was 69.97% for Q4 2025 at Myriad Genetics, roughly flat from 69.91% in the prior quarter.
  • Over five years, Gross Margin peaked at 100.0% in Q4 2021 and troughed at 33.24% in Q4 2022.
  • The 5-year median for Gross Margin is 69.98% (2023), against an average of 72.13%.
  • Year-over-year, Gross Margin crashed -6676bps in 2022 and then soared 3543bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 100.0% in 2021, then crashed by -67bps to 33.24% in 2022, then surged by 107bps to 68.67% in 2023, then rose by 4bps to 71.65% in 2024, then decreased by -2bps to 69.97% in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Gross Margin are 69.97% (Q4 2025), 69.91% (Q3 2025), and 71.23% (Q2 2025).